Q3 revenue of $22.6 million represents +8% growth year-over-year Positive net income of $3.1 million or 6 cents per share, and Adjusted EBITDA 1 of $7.2 million Fiscal 2024 guidance revised to between $83 and $85 million in revenue and Adjusted EBITDA guidance increased to a range of $17 to $19 million MONTREAL, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ:... Read More